



If you have questions please contact:

Maria Gutke Nigam, Account Manager Sweden, maria.gutkenigam@angelinipharma.com
Diana Stejmar, Account Manager Sweden, diana.stejmar@angelinipharma.com

Best wishes



Azadeh Roomiani
Brand Manager Nordics
azadeh.roomiani@angelinipharma.com
+46 730546053

About Angelini Pharma

Angelini Pharma was founded in Italy more than 100 years ago and has its Nordic office in Stockholm and headquarters in Rome. Angelini Pharma is the pharmaceutical Company of the Angelini Industries. We are committed to help patients fighting diseases with a focus on Mental Health (incl. Pain), Central Nervous System (CNS), Rare Diseases and Consumer Healthcare. Angelini Pharma has 3000 employees, and our products are available in more than 70 countries. Angelini Pharma Nordics was established in the Nordics in 2021.

Ontozry® (cenobamat) 12,5 mg odragerad tablett samt 25 mg, 50 mg, 100 mg, 150 mg och 200 mg filmdragerade tabletter. Rx F. Ontozry är indicerat som tilläggsbehandling av fokala anfall, med eller utan sekundär generalisering hos vuxna patienter med epilepsi, som inte kontrollerats tillräckligt trots tidigare behandling med minst två antiepileptika. ATC-kod: N03AX25 - antiepileptika, övriga antiepileptika. Kontraindikationer: Överkänslighet mot den aktiva substansen eller mot något hjälpämne, ärftligt kort QT-syndrom. Varningar: Patienter ska uppsöka läkare om tecken på självmordstankar/självmordsbeteende uppstår, samt om tecken och symptom på läkemedelsreaktion med eosinofili och systemiska symtom (DRESS) inträffar. Innehåller laktos. Cenobamat kan minska exponeringen av substanser som metaboliseras via CYP3A4, CYP2B6 samt öka exponeringen av substanser som metaboliseras via CYP2C19. Cenobamat rekommenderas inte till fertila kvinnor som inte använder preventivmedel eller vid amning. MAH: Angelini Pharma S.p.A. Lokal kontakt: Angelini Pharma Nordics, Östermalmstorg 1, 114 42 Stockholm. Datum för senaste översyn av SPC: 07/2022. För AUP och ytterligare information, se www.fass.se. ▼ Detta läkemedel är föremål för utökad övervakning.



Angelini Pharma Nordics Virtual epilepsy symposium

Wednesday 8th march 2023 | 09:30 – 15:00 CET

A scientific one-day symposium focusing on the various challenges in the treatment of epilepsy. The aim of this meeting is to support Nordic neurologists and nurses in the treatment and daily care for people living with epilepsy.

Danish and European experts share their insights on early clinical experiences with Ontozry (cenobamat), administration and interactions in medical treatment of epilepsy, learning disabilities within epilepsy and future trends in the treatment of epilepsy.

This event is aimed at neurologists and nurses with special interest in medical treatment of epilepsy.

Deadline for registering for this event 6th March 2023



← Scan QR code or register here
angelini.nemtilmeld.dk/2

Moderator

Charlotte Andersen, Medical Science Liaison, Angelini Pharma Nordics

Speakers

Professor Anne Sabers, Rigshospitalet, Copenhagen, Denmark

Anne Sabers is based at the Epilepsy Clinic at the Department of Neurology at Rigshospitalet in Copenhagen. Anne's primary areas of focus is on difficulties in treatment and management of patients with refractory seizures, sudden unexpected death (SUDEP) and treatment and women of childbearing age.

Professor Guido Rubboli, Epilepsihospitalet Filadelfia, Dianalund, Denmark

Guido Rubboli MD is Professor of Clinical Epileptology at the University of Copenhagen, and senior consultant at the Danish Epilepsy Center. His clinical activity involves primarily adult epilepsy, difficult-to-treat epilepsies, genetic epilepsies, and epilepsy surgery. He is currently Director of the ILAE VIREPA Course on Advanced EEG and member of the ILAE Task Forces on Transition in Care from Childhood to Adult and on SnoMED.

Dr Rhys Thomas, Newcastle University, United Kingdom

Dr Rhys Thomas is an Honorary Consultant in Epilepsy at the Royal Victoria Infirmary, where he leads on epilepsy, learning disability and genetic epilepsies. He is a Consultant in the NHS Highly Specialised Service for rare mitochondrial disorders as well as Clinical Senior Lecturer at Newcastle University where he acts as Co-Director of the Newcastle ERUK Doctoral Hub. He is an Associate Editor of Practical Neurology and Web Editor of Seizure, Trustee for Epilepsy Research UK, Treasurer for the British Branch of the International League Against Epilepsy and a medical advisor for Epilepsy Action. Dr Thomas' research focuses on the causes and consequences of epilepsy.

Dr Graeme Sills, University of Glasgow, United Kingdom

Dr Graeme Sills is currently Senior Lecturer in Pharmacology at the University of Glasgow. He is also Director of Education in the School of Cardiovascular & Metabolic Health, where he has strategic responsibility for 10 different undergraduate and postgraduate degree programmes. His research interests have been broad spectrum; mechanisms of drug action, animal models, genomics & pharmacogenomics, clinical trials, clinical pharmacology, and the phenomenon of drug resistance, all in the field of epilepsy. He has published several research papers, review articles, book chapters and online teaching modules on epilepsy mechanisms and antiepileptic drugs and sits on the editorial board of four scientific journals. He is a member of the ILAE (British Branch), the British Pharmacological Society and the British Neuro-science Association and has held several positions at Epilepsy Research UK.

Remuneration to the speaker is paid by Angelini Pharma.

Scientific programme

09:30 – 09:45 CET	Welcome	
09:30 – 10:45 CET	Treatment of therapy resistant focal epilepsy; clinical experiences of cenobamate	Dr Rhys Thomas, Newcastle university, United Kingdom
<i>OPTION 1</i> Session presented live again at 12 noon CET		
10:45 – 11:00 CET	Break	
11:00 – 12:00 CET	Drug-drug interactions in epilepsy; focus on cenobamate	Dr Graeme Sills, University of Glasgow, United Kingdom
	Strategies to handle interactions between lamotrigine and cenobamate; clinical approaches	Dr Christian Brandt Bethel Epilepsy Center, Bielefeld, Germany
	Q&A	Session speakers
12:00 – 13:00 CET	Treatment of therapy resistant focal epilepsy; clinical experiences of cenobamate	Dr Rhys Thomas, Newcastle university, United Kingdom
<i>OPTION 2</i> This session will also be presented in the morning		
13:00 – 14:00 CET	Udviklingshandicap og epilepsi – på tværs af faggrupper og sektorer	Professor Anne Sabers, Rigshospitalet, København
14:00 – 14:10 CET	Break	
14:10 – 14:55 CET	Future treatment trends within epilepsy: the path to precision medicine	Professor Guido Rubboli, Filadelfia Epilepsy Hospital Dianalund
14:55 – 15:00 CET	Meeting close	